… population of NSCLC patients with gefitinib and erlotinib in order to … With a large proportion
of patients undergoing EGFR … all patients according to different lines of gefitinib or erlotinib. …

… patients with EGFR-wt only, as gefitinib and erlotinib are well known to induce a marked
response and long PFS in patients … of the two agents directly in patients with EGFR-wt NSCLC. …

… (250 mg daily gefitinib or 150 mg daily erlotinib) between April … patients received gefitinib
and erlotinib treatment; therefore, we analyzed 17 plasma and 17 CSF samples from 15 patients…

… Both gefitinib and erlotinib showed effective activity and tolerable toxicity … gefitinib and erlotinib
in an enriched patient population. … Two patients of gefitinib group and 1 patient of erlotinib …

… on PFS or OS in patients treated with EGFR-TKIs. Erlotinib, gefitinib, and afatinib showed …
significantly longer in patients with the exon 19 deletion compared to patients with the exon …

… Previously treated patients with lung adenocarcinoma were randomly assigned … gefitinib
or erlotinib. This study aimed to investigate the noninferiority of gefitinib compared with erlotinib. …

… between gefitinib-treated and erlotinib-treated patients with NSCLC who had failed prior
chemotherapy. Our analysis shows that gefitinib and erlotinib in pretreated patients with …

… of EGFR-TKIs in this patient population. Herein, we conducted a retrospective study to
assess the efficacy of gefitinib/erlotinib and afatinib in patients with advanced-stage lung …

… For patients who received gefitinib or erlotinib for more than … Patients who used either
gefitinib or erlotinib as second-line … gefitinib or erlotinib as second-line therapy because erlotinib …

… In 74 patients with adequate specimens for molecular analysis, 4 (5.4%) had EGFR … of
advanced squamous cell lung cancer patients. Erlotinib and gefitinib had a similar efficacy in …